Inhibikase Therapeutics, Inc.

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in Inhibikase Therapeutics, Inc..

News

Inhibikase Therapeutics First Half 2024 Earnings: US$1.39 loss per share (vs US$2.08 loss in 1H 2023)

Simply Wall St Inhibikase Therapeutics ( NASDAQ:IKT ) First Half 2024 Results Key Financial Results Net loss: US$9.61m (loss narrowed...\n more…

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Seeking Alpha: Transcripts Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript...\n more…

Inhibikase Therapeutics reports Q2 EPS (66c), consensus (67c)

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Globe Newswire Company to host conference call on August 15, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a...\n more…

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Globe Newswire BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or Company ), a clinical-stage pharmaceutical company developing protein kinase...\n more…

Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders

SeekingAlpha.com: All News Inhibikase Therapeutics (IKT) filed a prospectus for resale of up to 4,761,904 shares of common stock by a selling stockholder.\n more…